FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385330607> ?p ?o ?g. }

• W4385330607 endingPage "347" @default.
• W4385330607 startingPage "340" @default.
• W4385330607 abstract "Neuroinflammation after spinal cord injury (SCI) can lead to long-term damage in neural tissue, which can cause the destruction and dysfunction of the neurological system. Roflupram (ROF), a selective phosphodiesterase 4 inhibitor, may play a protective role against neuropathological diseases, but the specific role of ROF in SCI treatment is unknown.The study intended to investigate the anti-inflammatory mechanism and therapeutic effects of ROF to determine if it can attenuate lipopolysaccharide (LPS)-induced microglia that induces neuroinflammation and decrease neural-tissue damage following an SCI.The research team performed an animal study.The study took place at the Fourth Affiliated Hospital of Harbin Medical University in Harbin, China.The animals were female C57BL/6 mice, aged 8 weeks and weighing approximately 20 g.For the in-vitro study, the research team divided BV2 microglial cells into three groups: (1) the control group, which received no LPS stimuli and no ROF treatment, (2) the LPS group, which received LPS stimuli but no ROF treatment, and (3) LPS+ROF group, which received both LPS stimuli and ROF treatment. For the in-vivo study, the research team randomly divided the mice into three groups: (1) the sham group, for which the team didn't induce SCI and which received no ROF treatment (2) the SCI group, for which the team induced SCI but which received no ROF treatment, and (3) the SCI+ROF group, for which the team induced SCI and which received the ROF treatment.The research team evaluated: (1) the cell viability of the BV2 microglia cells after five doses of ROF and the RNA levels of inflammatory-activation-related factors, the inflammatory pathway; (2) in-vitro inhibition of inflammation in LPS-activated microglia; (3) the anti-neuroinflammatory role of ROF after SCI induction in vitro; and (4) the role of ROF in neural-structure protection and locomotor-function recovery in vitro.In the in-vitro study, the ROF attenuated microglial inflammation through the inhibition of the NLRP3 inflammasome in vitro, reduced neuroinflammation, and protected against neuronal loss. In the in-vivo study with mice, the ROF: (1) improved the functional recovery of locomotor skills after induction of SCI; (2) acted in an anti-inflammatory role in SCI, restraining microglial inflammation by inhibition of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3) inflammasome and reduction of caspase-1-dependent, interleukin-1 beta (IL)-1β; and (3) reduced neuronal death and protected against tissue loss, improving functional recovery after an SCI.The current study demonstrated that ROF can reduce the levels of inflammation in the tissue after spinal cord injury by modulating the AMPK/NLRP3 signaling pathway, thereby promoting the recovery of motor function in mice. ROF is a promising drug for prevention of neural-tissue damage following neural injury." @default.
• W4385330607 created "2023-07-29" @default.
• W4385330607 creator A5011881849 @default.
• W4385330607 creator A5048959337 @default.
• W4385330607 creator A5050958365 @default.
• W4385330607 creator A5056522993 @default.
• W4385330607 creator A5087399337 @default.
• W4385330607 date "2023-10-01" @default.
• W4385330607 modified "2023-09-28" @default.
• W4385330607 title "Phosphodiesterase 4 Inhibitor Roflupram Suppresses Inflammatory Responses Using Reducing Inflammasome in Microglia After Spinal Cord Injury." @default.
• W4385330607 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37499151" @default.
• W4385330607 hasPublicationYear "2023" @default.
• W4385330607 type Work @default.
• W4385330607 citedByCount "0" @default.
• W4385330607 crossrefType "journal-article" @default.
• W4385330607 hasAuthorship W4385330607A5011881849 @default.
• W4385330607 hasAuthorship W4385330607A5048959337 @default.
• W4385330607 hasAuthorship W4385330607A5050958365 @default.
• W4385330607 hasAuthorship W4385330607A5056522993 @default.
• W4385330607 hasAuthorship W4385330607A5087399337 @default.
• W4385330607 hasConcept C118552586 @default.
• W4385330607 hasConcept C126322002 @default.
• W4385330607 hasConcept C150903083 @default.
• W4385330607 hasConcept C181199279 @default.
• W4385330607 hasConcept C185592680 @default.
• W4385330607 hasConcept C207001950 @default.
• W4385330607 hasConcept C2776914184 @default.
• W4385330607 hasConcept C2777209026 @default.
• W4385330607 hasConcept C2778334475 @default.
• W4385330607 hasConcept C2778754761 @default.
• W4385330607 hasConcept C2779830541 @default.
• W4385330607 hasConcept C2780775167 @default.
• W4385330607 hasConcept C55493867 @default.
• W4385330607 hasConcept C62826618 @default.
• W4385330607 hasConcept C71924100 @default.
• W4385330607 hasConcept C86803240 @default.
• W4385330607 hasConcept C87753298 @default.
• W4385330607 hasConcept C98274493 @default.
• W4385330607 hasConceptScore W4385330607C118552586 @default.
• W4385330607 hasConceptScore W4385330607C126322002 @default.
• W4385330607 hasConceptScore W4385330607C150903083 @default.
• W4385330607 hasConceptScore W4385330607C181199279 @default.
• W4385330607 hasConceptScore W4385330607C185592680 @default.
• W4385330607 hasConceptScore W4385330607C207001950 @default.
• W4385330607 hasConceptScore W4385330607C2776914184 @default.
• W4385330607 hasConceptScore W4385330607C2777209026 @default.
• W4385330607 hasConceptScore W4385330607C2778334475 @default.
• W4385330607 hasConceptScore W4385330607C2778754761 @default.
• W4385330607 hasConceptScore W4385330607C2779830541 @default.
• W4385330607 hasConceptScore W4385330607C2780775167 @default.
• W4385330607 hasConceptScore W4385330607C55493867 @default.
• W4385330607 hasConceptScore W4385330607C62826618 @default.
• W4385330607 hasConceptScore W4385330607C71924100 @default.
• W4385330607 hasConceptScore W4385330607C86803240 @default.
• W4385330607 hasConceptScore W4385330607C87753298 @default.
• W4385330607 hasConceptScore W4385330607C98274493 @default.
• W4385330607 hasIssue "7" @default.
• W4385330607 hasLocation W43853306071 @default.
• W4385330607 hasOpenAccess W4385330607 @default.
• W4385330607 hasPrimaryLocation W43853306071 @default.
• W4385330607 hasRelatedWork W2040423913 @default.
• W4385330607 hasRelatedWork W2750323490 @default.
• W4385330607 hasRelatedWork W2804482952 @default.
• W4385330607 hasRelatedWork W3196858661 @default.
• W4385330607 hasRelatedWork W3202708309 @default.
• W4385330607 hasRelatedWork W4281290245 @default.
• W4385330607 hasRelatedWork W4288053254 @default.
• W4385330607 hasRelatedWork W4293561577 @default.
• W4385330607 hasRelatedWork W4361005848 @default.
• W4385330607 hasRelatedWork W4385751300 @default.
• W4385330607 hasVolume "29" @default.
• W4385330607 isParatext "false" @default.
• W4385330607 isRetracted "false" @default.
• W4385330607 workType "article" @default.